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1 year of patients included from October 2011 until Decem-
ber 2014 were analyzed.  Results: Within 39 months, 323 pa-
tients from 7 tertiary dermatology centers in Switzerland 
were recruited in the SDNTT; 165 patients received biologics 
and 158 conventional systemic therapies . Patients treated 
with biologics had a significantly higher severity (PASI 11.3 
vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%;  p  ≤ 
0.005,  p  ≤ 0.013,  p  ≤ 0.001) and a longer duration of illness 
(19.2 vs. 14.4 years,  p  ≤ 0.003) compared to patients starting 
a conventional systemic treatment. PASI reduction was sat-
isfying in both treatment groups, with 60.6% of patients 
treated with biologics achieving PASI75 after 1 year com-
pared to 54.2% of patients receiving conventional systemic 
 Keywords 
 Psoriasis · Swiss psoriasis registry · Conventional systemic 
treatment · Biologics 
 Abstract 
 Background: The Swiss psoriasis registry SDNTT (Swiss Der-
matology Network for Targeted Therapies) records the long-
term safety and effectiveness of systemic treatment regi-
mens for psoriasis.  Patients and Methods: Patients with 
moderate to severe psoriasis are included in the SDNTT 
when treatment with a conventional systemic agent or bio-
logic is initiated that was not previously used by the respec-
tive patient. Patients are followed over a 5-year period. Clin-
ical data are obtained every 3–6 months using standardized 
case report forms. Here, baseline data and follow-up data for 
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drugs (nonsignificant). On average, the drug survival in pa-
tients receiving a biologic therapy was significantly longer 
than those receiving conventional systemic treatments
(30.5 vs. 19.2 months,  p  ≤ 0.001).  Conclusions: In the real-
world setting of a prospective national therapy registry, the 
application of current therapeutic guidelines for patients 
with moderate to severe psoriasis resulted in a PASI reduc-
tion of approximately 70% within the first year of treatment, 
but current therapeutic targets of PASI75 and PASI90 were 
reached in only 58 and 36% of patients, respectively, at 1 
year, highlighting a gap in efficacy between selective clinical 
trials and the real-world setting.  © 2017 S. Karger AG, Basel 
 Introduction 
 Patient registries are systematic, prospective, proto-
col-driven collections of patient data. They generate 
knowledge on the safety and efficacy of drugs under rou-
tine conditions and on their mechanisms of action  [1] . In 
contrast to randomized clinical trials, registries usually 
have less stringent inclusion criteria. Furthermore, they 
allow long-term study of disease and therapy  [1, 2] . In ad-
dition to the analysis of effectiveness under day-to-day 
conditions, another asset of patient registries is the re-
cording of drug safety data (pharmacovigilance) even in 
patient groups that are generally excluded from random-
ized controlled trials because of comorbidities, co-medi-
cations or other criteria  [3] .
 The Swiss Dermatology Network for Targeted Thera-
pies (SDNTT) of the Swiss Society of Dermatology and 
Venereology (SGDV) was established in 2010 to study the 
efficacy and safety of approved systemic therapies avail-
able for psoriasis in Switzerland.
 The SDNTT is a noninterventional observational reg-
istry which is based on an electronic case report form pro-
vided by the Centre of Excellence for Health Services Re-
search in Dermatology (CVderm, Competenzzentrum 
Versorgungsforschung in der Dermatologie) at the Uni-
versity Medical Center Hamburg-Eppendorf, Germany.
 Documentation is managed using a patient-based data-
base as a registry. Since October 2011, adult patients with 
moderate to severe psoriasis newly treated with a systemic 
therapy not previously used by the respective patient were 
included prospectively into the registry upon provision of 
informed consent. The patients were included in the regis-
try for a period of 5 years regardless of subsequent treat-
ment changes. The SDNTT aims to collect data of at least 
500 patients during an observation period of 5 years.
 The participating centers are the University Hospitals 
of Basel, Lausanne, Bern, Zurich, and Geneva as well as 
the Cantonal Hospitals of St. Gallen and Aarau.
 Aims 
 The purpose of this prospective analysis, focusing on 
a period of 1 full year of systemic therapy, was to charac-
terize changes in disease severity in patients with psoriasis 
and/or psoriatic arthritis subsequent to beginning a new 
systemic therapy with a biologic (including adalimumab, 
etanercept, infliximab, or ustekinumab) or a convention-
al systemic therapy (including methotrexate, fumaric 
acid esters, cyclosporine, acitretin, or systemic PUVA). 
Furthermore, the duration of treatment with the same 
systemic drug (drug survival) was analyzed.
 Patients and Methods 
 For further details, see the supplementary materials (for all on-
line suppl. material, see www.karger.com/doi/10.1159/000452740) 
 [4, 5] ( Fig. 1 ,  2 ).
 Results 
 A total of 323 patients were included in the SDNTT 
registry between October 2011 and December 2014.
 Table 1 shows the distribution of different treatments at 
inclusion and the number of visits within the first year of 
observation. Overall, 165 patients on biologics and 158 
patients on conventional systemic treatment were includ-
ed into the SDNTT. Adalimumab was the most frequent-
ly used biologic, and among the conventional systemic 
drugs, methotrexate was most often prescribed. More 
than half of the patients had received phototherapy before 
being included in the registry (70.3% in the biologic arm, 
56.3% in the conventional systemic treatment arm). As to 
the sequence of systemic treatments, we observed that 
39.2% of patients starting a conventional systemic treat-
ment had switched from another prior conventional 
treatment, whereas only 8.9% switched from a prior bio-
logic to a conventional systemic treatment, and nearly 
half of the patients switched from a prior biologic at in-
clusion (47.9%) to another biologic drug.
 Patients treated with biologics had a significantly high-
er disease activity at inclusion than patients treated with 
conventional systemic agents: PASI (Psoriasis Area and 
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Severity Index) 11.3 vs. 9.2,  p  ≤ 0.005; BSA (body surface 
area) 15.6 vs. 11.9,  p  ≤ 0.013. A subanalysis within the 
treatment groups revealed that the mean PASI in biolog-
ic treatment starters ranged from 10.2 for ustekinumab
( n = 55, SD 5.9) to 12.3 for etanercept ( n = 33, SD 7.5). 
For patients starting a conventional systemic treatment 
upon inclusion the average PASI ranged from 7.8 in fu-
maric acid esters ( n = 27, SD 5.4) to 9.0 in methotrexate 
( n = 119, SD 5.8). Within the very small subgroups (each 
 n = 6) of infliximab, cyclosporine A, and retinoid, patients 
had a relatively high PASI with an average of 13.0 ( n = 18, 
SD 8.3) at inclusion.
 Both groups had comparable rates of nail involvement: 
biologic therapy 62.4%, conventional systemic therapy 
58.2% (nonsignificant) and impairment of quality of life: 
biologic therapy 11.8 (SD 7.8), conventional systemic 
therapy 10.7 (SD 6.6, nonsignificant). Patients starting a 
biologic treatment had suffered from psoriasis for a sig-
nificantly longer period of time compared to patients who 
received a conventional systemic treatment (biologic 
therapy 19.2 years, conventional systemic therapy 14.4 
years,  p  ≤ 0.003). Patients in the biologic treatment group 
were significantly more frequently affected with psoriasis 
arthritis (biologic therapy 36.4%, conventional systemic 
therapy 10.8%,  p  ≤ 0.001) ( Table 2 ).
 Effect of Systemic Therapy on Disease Activity 
 Table 3 and  Figure 3 show the evolution of mean PASI 
scores during the first treatment year for all treatment 
subgroups that contained at least 10 patients. After 3 
 Table 1.  Visits by inclusion therapy: biologics and conventional 
systemics
Visit 1
0 mo
Visit 2
3 mo
Visit 3
6 mo
Visit 4
12 mo
Biologics
Adalimumab 69 53 48 27
Etanercept 33 25 18 11
Infliximab 6 4 4 4
Ustekinumab 56 41 40 24
Golimumab 1 0 0 0
Total 165 123 110 66
Conventional systemics
Cyclosporine A 6 3 2 0
Fumaric acid esters 27 14 12 7
Methotrexate 119 81 56 29
Retinoid 6 3 3 1
Total 158 101 73 37
Total 323 224 183 103
Numbers of patients are shown. mo, months.
Patients with
• Moderate to severe psoriasis (with/without psoriatic arthritis)
• Start of previously unused systemic therapy
,QIRUPHGFRQVHQWDQGDJHG\HDUV
• Ability to complete CRF in German or French language
7 clinics in Switzerland
8QWLO'HFHPEHU
Physician and patient CRF (paper or online)
• Antipsoriatic and concomitant treatment
• Clinical status
• Clinical parameters of psoriasis and psoriatic arthritis
• Adverse events and comorbidity
• Patient demographics
• Quality of life and health state
• Patient benefit and treatment goals
Follow-up: every 3/6 months
SD
N
TT
 re
gi
st
ry
(d
at
a 
co
lle
ct
io
n 
si
nc
e
2
FW
RE
HU





n 
patients
9LVLWVDIWHUVW\HDURUDIWHU
stop of inclusion drug
n 
visits
Baseline
characteristics
Inclusion 
treatment
Drug 
effectiveness
Drug 
persistence
Methotrexate
Fumaric acid esters
Cyclosporine
Retinoids
Adalimumab
Ustekinumab
Etanercept
Infliximab
Golimumab
0 20 40 60 80
Patients, n
100 120 140
 Fig. 1. Flowchart of Patients and Methods. CRF, case report form. 
 Fig. 2. Number of patients with conventional systemic and bio-
 logic treatment at inclusion in SDNTT. 
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months of continuous biologic treatment 43.1% of pa-
tients had experienced an improvement in PASI of at least 
75% compared to baseline value, and nearly every fifth 
patient reached PASI90 (18.7%). These response rates 
further increased to 60.6% for PASI75 and 33.3% for 
PASI90 after 1 year of continuous treatment. At this 
point, the mean PASI reduction was 70.8%. The mean 
absolute PASI score for patients on biologic treatment 
was 4.0 after 3 months and 3.3 after 12 months.
 After 3 months of conventional systemic treatment 
35.6% of patients had achieved a PASI reduction of at 
least 75%, further improving to 54.1% at 12 months. The 
percentages of patients achieving PASI90 were 13.9% at 3 
months and 40.5% at 12 months. The mean PASI reduc-
tion was 76.1%. Patients on conventional systemic treat-
ment had a mean absolute PASI score of 3.5 after 3 months 
and 2.2 after 12 months.
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Time, months
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 Table 2.  Sociodemographic and clinical parameters by inclusion treatment group
Biologic treatment  Conventional systemic treatment
n mean min max SD  n mean min max SD
Female, % 165 32.7 158 31.6
Nail involvement, % 165 62.4 158 58.2
Psoriatic arthritis, %*** 165 36.4 158 10.8
Duration of illness, years** 145 19.2 0.0 63.0 13.9 146 14.4 0.0 59.0 13.0
Age, years 165 47.1 20.0 79.0 14.2 158 47.1 18.0 82.0 16.0
Weight, kg 164 48.0 165.0 84.1 22.3 158 43.0 148.0 81.9 19.8
PASI** 164 11.3 0.0 50.4 7.5 158 9.2 0.0 32.4 6.1
BSA* 164 15.6 0.0 98.0 14.4 158 11.9 0.0 60.0 12.0
DLQI 149 11.8 0.0 30.0 7.8 151 10.7 0.0 27.0 6.6
 Significant differences: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
 Table 3.  Mean PASI within the first treatment year
Visit 1 (0 mo) Visit 2 (3 mo) Visit 3 (6 mo)  Visit 4 (12 mo)
PASI n PASI n PASI n  PASI n
Adalimumab 11.4 69 3.6 53 2.5 48 2.8 27
Etanercept 12.3 33 6.2 25 4.9 18 3.8 11
Ustekinumab 10.2 55 2.9 40 3.1 40 2.8 24
Pooled biologics 11.3 164 4.0 122 3.3 110 3.3 66
Fumaric acid esters 7.8 27 4.9 14 3.8 12 2.4 7
Methotrexate 9.0 119 3.3 80 2.2 55 2.2 28
Pooled conventional systemics 9.2 158 3.5 100 2.6 72 2.2 36
Only treatment subgroups with at least 10 patients at inclusion visit are shown. mo, months.
 Fig. 3. PASI reduction within the first treatment year. 
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 A comparison of response rates between patients 
treated with biologics and patients treated with conven-
tional systemic therapy did not reveal significant dif-
ferences in PASI75 or PASI90 at 3 and 12 months. The 
PASI75, for example, was 43.1% for patients treated with 
biologics versus 35.6% for patients receiving convention-
al systemic therapy at 3 months (nonsignificant), and 60.6 
versus 54.1%, respectively, at 12 months (nonsignificant) 
( Table 4 ).
 Treatment Survival 
 Since the inclusion of the first patient in October 2011, 
a total observation time on systemic treatment of 303.96 
patient-years has been registered in the SDNTT. The 
mean observation time of the 323 included patients was 
11.3 months (range 0–37, SD 9.4), and no significant dif-
ference was observed between the treatment groups (bio-
logics 11.7 months, conventional systemic therapy 10.8 
months, nonsignificant).
 Table 5 depicts the drug survival, or the mean time pe-
riod for which a patient remained on the treatment initi-
ated at inclusion before the treatment was switched to 
another medication or stopped. The cause of discontinu-
ation was available for 50 discontinuations of biologic 
treatment and 115 of conventional systemics. Most treat-
ments were stopped due to lack or loss of efficacy (52.0% 
in the biologics group, 29.6% in the conventional treat-
ment group). Side effects were reported in 22.0 and 32.2%, 
respectively. Other reasons for discontinuation were 
complete disease control (13.0% in the conventional sys-
temic treatment group, 0% in the biologics group) and 
patient’s wish (6.1% in the conventional systemic treat-
ment group, 14.0% in the biologics group). There were 2 
discontinuations of undisclosed motivation in the biolog-
ics group and 4 in the conventional systemic treatment 
group.
 Analysis of treatment survival revealed that patients 
remained on the initial treatment longer if it was a bio-
logic. Patients starting on biologics had a mean treatment 
duration with the same biologic of 30.5 months (95% CI 
27.8–33.2), which was significantly longer than that ob-
served for patients treated with conventional systemic 
therapy (19.2 months, 95% CI 16.0–22.5,  p  ≤ 0.001)
( Table 5 ;  Fig. 4 ).
 Adverse events between biologic and conventional 
systemic treatment occurred at equal rates except for gas-
trointestinal disorders (4.6 patients/100 patient-years in 
biologics vs. 16.8 patients/100 patient-years in conven-
tional systemic treatment; 95% CI 11.9–23.0 vs. 2.4–8.0, 
 p  ≤ 0.05).
 After 18 months, 50% of the patients in the systemic 
treatment group had stopped their therapy due to situa-
tions representing a contraindication (i.e., methotrexate 
stop due to planned pregnancy), adverse reactions, or 
 Table 5.  Mean treatment duration in months
 n Mean Min Max SD
Adalimumab 69 11.5 0.0 36.8 9.7
Etanercept 33 9.5 0.0 29.1 8.3
Ustekinumab 56 10.2 0.0 32.9 8.4
Biologics 165 10.7 0.0 36.8 8.8
Fumaric acid esters 27 9.3 0.0 31.4 9.3
Methotrexate 119 7.7 0.0 36.0 7.2
Conventional systemics 158 7.9 0.0 36.0 7.5
Duration due to termination of treatment or observation. Only 
treatment subgroups with at least 10 patients at inclusion visit are 
shown.
 Table 4.  PASI75 and PASI90 within the first treatment year; no significant differences were seen
PASI75  PASI90
visit 2 (3 mo) visit 3 (6 mo) visit 4 (12 mo) visit 2 (3 mo) visit 3 (6 mo) visit 4 (12 mo)
Adalimumab 53 (41.5%) 48 (60.4%) 27 (66.7%) 53 (18.9%) 48 (39.6%) 27 (44.4%)
Etanercept 25 (24.0%) 18 (33.3%) 11 (27.3%) 25 (4.0%) 18 (16.7%) 11 (18.2%)
Ustekinumab 41 (53.7%) 40 (70.0%) 24 (75.0%) 41 (26.8%) 40 (37.5%) 24 (33.3%)
Biologics 123 (43.1%) 110 (58.2%) 66 (60.6%) 123 (18.7%) 110 (34.5%) 66 (33.3%)
Fumaric acid esters 14 (14.3%) 12 (25.0%) 7 (28.6%) 14 (7.1%) 12 (0.0%) 7 (14.3%)
Methotrexate 81 (37.0%) 56 (53.6%) 29 (58.6%) 81 (13.6%) 56 (28.6%) 29 (44.8%)
Conventional systemics 101 (35.6%) 73 (47.9%) 37 (54.1%) 101 (13.9%) 73 (23.3%) 37 (40.5%)
Only treatment subgroups with at least 10 patients at inclusion visit are shown. mo, months.
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treatment success. In the biologic treatment group, the 
survival function decreased to 75% after approximately 
40 months ( Fig. 4 ).
 Discussion 
 One of the aims of the SDNTT is to increase our in-
sight into drug safety and efficacy in a real-life setting in 
order to optimize the management of patients suffering 
from psoriasis and psoriatic arthritis. During the period 
analyzed by our study, more than 2/3 of the included pa-
tients in the SDNTT registry suffered from moderate to 
severe psoriasis: DLQI (Dermatology Life Quality Index) 
>10 or BSA >10 or PASI >10.
 The average PASI improvement reached 70.8% in the 
biologic treatment group and 76.1% in the conventional 
treatment group after 1 year of treatment (nonsignifi-
cant). No significant differences in PASI improvement 
was observed after 3 months or after 1 year of follow-up 
in patients receiving conventional systemic treatment 
(PASI75 54.1%) compared to treatment with a biologic 
(PASI75 60.6%). Our data suggests, however, that in the 
specific patient population studied, patients treated with 
biologics when analyzed as a pooled group had a trend to 
more rapid improvement in their PASI score than the 
group of patients treated with conventional systemic 
treatments (biologics PASI75 43.1, 58.2, and 60.6% vs. 
conventional systemic treatments 35.6, 47.9, and 54.1% 
after 3, 6, and 12 months, respectively, nonsignificant).
 The rates of response to biologics in the SDNTT dif-
fered somewhat from those of published randomized 
controlled trials. In our registry, 66.7% of patients treated 
with adalimumab reached a PASI75 response after 1 year. 
In a trial on adalimumab 40 mg every 2 weeks, 53% of the 
patients treated with the regular doses of adalimumab 
showed a PASI75 response after 52 weeks of treatment 
 [6] . In the CHAMPION randomized controlled trial, 
adalimumab was compared to methotrexate and placebo 
in psoriasis patients. After 16 weeks, 79.6% of adalimum-
ab-treated patients achieved PASI75 compared to 35.5% 
of methotrexate-treated patients ( p < 0.001 methotrexate 
vs. adalimumab) and 18.9% of patients receiving placebo 
( p < 0.001 placebo vs. adalimumab)  [7] . In the real-world 
setting of our registry, only 41.5% of adalimumab and 
37% of methotrexate patients reached the PASI75 at 12 
weeks. However, the results cannot be directly compared, 
as the data from our registry were taken at week 12 (com-
pared to week 16), the numbers of patients within the dif-
ferent treatment groups in our registry were uneven, and 
the groups were nonhomogeneous. It should be noted 
that the mean baseline PASI was relatively low compared 
to those reported in clinical trials, and comparable PASI 
reduction rates were therefore harder to achieve. Never-
theless, satisfying absolute PASI scores were achieved in 
the real-world setting of this prospective national therapy 
registry (3.3 at week 52 in biologics and 2.2 in conven-
tional systemic treatment).
 A randomized phase III trial with 618 patients on etan-
ercept 50 mg twice weekly showed that 47% of patients 
achieved PASI75 at week 12  [8] .  In our registry, only
23% of etanercept-treated patients achieved PASI75 at 3 
months.
 A multicenter, phase III, double-blind, placebo-con-
trolled study (PHOENIX 2) with moderate to severe 
plaque psoriasis patients found that more patients treated 
with ustekinumab (45 or 90 mg) achieved PASI75 at week 
12 than those treated with placebo (67 and 76%, respec-
tively, vs. 4%)  [9] . In our real-life setting, we observed
that ustekinumab showed a lower response rate of 53.7% 
achieving PASI75 at week 12.
 It has been observed that, in general, biologic therapies 
can lose effectiveness over time  [10] . The drug survival of 
biologics in our Swiss registry was similar to other na-
tional registries. The British registry  [11] demonstrated 
that ustekinumab had the highest drug survival in biolog-
ic-naive patients, followed by adalimumab. A multicenter 
1.0
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 Fig. 4. Drug survival: treatment duration of biologic and conven-
tional systemic treatment; censoring due to observation period. 
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Dutch study of 213 patients found a 1-year survival rate 
of 85% for ustekinumab, 74% for adalimumab, and 68% 
for etanercept, concluding that ustekinumab had a sig-
nificantly higher drug survival than etanercept  [12] . In 
the SDNTT, significant differences in drug survival were 
only detectable between biologics and conventional sys-
temic therapy, because both the duration of follow-up 
and the number of patients on different drugs were still 
too small for a subgroup analysis of each drug. There are 
few studies on factors associated with drug survival of 
conventional systemic treatment. It has been shown that 
comorbidities are a predictor for discontinuation of treat-
ment and that lack of folic acid supplementation in pa-
tients treated with methotrexate is associated with treat-
ment dropout  [13] .
 Reported gastrointestinal symptoms and/or side ef-
fects were significantly more frequent in the convention-
al systemic treatment group (16.8 patients/100 patient-
years in conventional systemic treatment vs. 4.6 pa-
tients/100 patient-years in biologic treatment,  p  ≤ 0.05). 
Correspondingly, gastrointestinal adverse events are 
known to lead to a discontinuation of treatment, espe-
cially in patients treated with fumaric acid esters  [14] , 
and nausea is frequent in methotrexate treatment as 
well.
 As a whole, adverse events were evenly distributed in 
both treatment groups. Comparable to this study, a meta-
analysis of 25 randomized clinical trials evaluating the ef-
ficacy and safety of systemic long-term treatments in
patients with moderate to severe psoriasis showed no
relevant differences in safety concerning rates of adverse 
events and serious adverse events between conventional 
and biologic systemic therapy  [15] . A more detailed anal-
ysis of reasons for treatment termination and differences 
in duration of treatment is planned for the future when 
there are enough patients in each treatment group to do 
subgroup analysis for each drug. Recently, a Spanish reg-
istry inception cohort analyzed the risk of serious adverse 
events associated with biologic and nonbiologic psoriasis 
systemic therapy in randomized controlled trials and in a 
real-world setting. It was shown that the risks of adverse 
events are different between randomized clinical trials 
and real-world registries  [16] .
 Strengths and Limitations 
 The SDNTT registry has its strength in the prospective 
real-world study design and the high quality of patient 
data that were systematically collected, independently an-
alyzed, and monitored by multiple centers in Switzerland. 
A further strength is the relatively long follow-up data 
available for individual patients despite the young age of 
the registry and extensively collected data points allowing 
numerous covariates to be analyzed in the future.
 This study has limited statistical power due to the cur-
rently relatively small number of cases with long-term 
follow-up in this rather young registry. Therefore, only 
the results of patients with adalimumab, etanercept, 
ustekinumab, fumaric acid esters, and methotrexate 
were used for direct comparisons. The limited power also 
precluded determining a potential difference of efficacy
between conventional drugs and biologics, even though 
there was a trend towards higher efficacy of biologics. 
Another limitation is that the mean PASI at the time of 
inclusion and start of treatment was higher in the group 
of patients subsequently treated with biologics. Further 
analyses, including subgroup analyses of patients as well 
as medium-term safety analysis will be performed once 
the number of included patients allows sufficient statis-
tical power.
 Conclusion 
 The SDNTT registry was established as a noninterven-
tional observational registry in 2010 to study the efficacy 
and safety of approved systemic therapies available for 
psoriasis in Switzerland as a first step towards nation-
wide long-term research of systemic psoriasis therapy in-
tegrating patient benefit, efficacy, and safety under real-
life conditions.
 At 1 year of follow up, our data indicate no difference 
in efficacy between biologics and conventional systemic 
therapy as yet. However, the duration of treatment in pa-
tients receiving a biologic therapy was significantly longer 
than those receiving conventional systemic treatment. 
Due to currently limited statistical power, analyses such 
as the reasons for discontinuation are planned for a later 
time point.
 In the SDNTT, an overall PASI reduction of approxi-
mately 70% within the first year of treatment was seen, 
but the current therapeutic target of PASI75 was reached 
in only 61 and 54% of patients on biologics and conven-
tional systemic drugs, respectively, after 1 year. These re-
sults demonstrate a gap in efficacy between randomized 
placebo-controlled clinical trials including only selected 
patient cohorts and the real-world setting of patients 
with moderate to severe psoriasis as documented by our 
registry.
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